When Will We Have a Flu/COVID-19 Vaccine Combo?
Novavax (NASDAQ: NVAX) was one of the top stocks in the entire stock market in 2020, running up from $4 a share on Jan. 2 all the way to $119 a share by Dec. 31. It had this magnificent run as Wall Street became more and more convinced that the company's COVID-19 vaccine would make a lot of money. And while Novavax's vaccine still hasn't been approved by the Food and Drug Administration (FDA), many investors remain bullish that it will be soon.
The stock market, however, is a forward-looking mechanism. So what's in the pipeline? Novavax also has a flu vaccine with great phase 3 data. Investors are expecting that drug to also win FDA approval. But what's tantalizing for long-term shareholders are the company's plans for vaccination over the next decade. In this video from Motley Fool Live, recorded on May 14, Corinne Cardina, healthcare and cannabis bureau chief at Fool.com, and Motley Fool writer Taylor Carmichael discuss the prospects for a COVID-19/Flu combo shot.
Source Fool.com
